ArticleHuman genomics2025
miR-144-3p targeting FLRT3 in osteogenic differentiation of mandibular bone marrow mesenchymal stem cells.
Article in Human genomics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Exploring miR-144-3p Expression and its Diagnostic Value in Peri-Implantitis.Oral health & preventive dentistry · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundFibronectin Leucine-Rich Transmembrane Protein 3 (FLRT3) plays a crucial role in craniofacial development and osteogenic differentiation, yet the regulatory mechanisms of microRNAs (miRNAs) on FLRT3 remain largely unexplored. This study identifies miR-144-3p as a miRNA that targets FLRT3 and investigates its role in osteogenic differentiation. These findings provide a foundation for the development of miRNA-based therapeutic strategies for craniofacial diseases and contribute to a deeper understanding of FLRT3's involvement in osteogenesis.
methodsMandibular bone marrow mesenchymal stem cells (MBMSCs) were isolated from SD rats using whole bone marrow and limiting dilution techniques. Flow cytometry and differentiation assays for osteogenesis and adipogenesis were conducted to characterize the cells. Bioinformatics analysis was employed to identify miRNAs that regulate FLRT3, with RT-qPCR used to select the most influential miRNA. A dual-luciferase reporter assay was performed to validate the interaction between the miRNAs and FLRT3. RT-qPCR measured miR-144-3p expression during osteogenic induction. Alkaline phosphatase and Alizarin Red S staining were used to assess the role of miR-144-3p in osteogenic differentiation. The impact of miR-144-3p on FLRT3, BMP2, and RUNX2 expression during osteogenesis was further evaluated by RT-qPCR.
resultsMBMSCs exhibited spindle-shaped morphology, high purity, and robust proliferative capacity, with flow cytometry confirming positive expression of CD29 and CD90. Bioinformatics analysis identified four miRNAs associated with FLRT3: miR-27a-3p, miR-27b-3p, miR-199a-3p, and miR-144-3p, with miR-144-3p showing the strongest correlation. Dual-luciferase assays confirmed that FLRT3 is a target gene of miR-144-3p. Functional assays revealed that the miR-144-3p mimic decreased FLRT3 expression, while the inhibitor increased it. During osteogenic differentiation, miR-144-3p mimic inhibited osteogenesis, while the inhibitor enhanced it, corresponding to alterations in the expression of FLRT3, BMP2, and RUNX2.
conclusionmiR-144-3p regulates the osteogenic differentiation of MBMSCs by targeting and modulating FLRT3, with FLRT3 being a direct target of miR-144-3p. During osteogenic differentiation, miR-144-3p inhibits osteogenesis by downregulating FLRT3, BMP2, and RUNX2 expression. This study not only elucidates the miRNA-mediated regulatory mechanism in osteogenesis but also offers a novel strategy for mandibular bone defect repair.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.